{"id":7995,"date":"2026-04-28T14:10:23","date_gmt":"2026-04-28T14:10:23","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=7995"},"modified":"2026-06-30T15:04:44","modified_gmt":"2026-06-30T15:04:44","slug":"last-12-months-prevalence-of-psychoactive-substance-use-among-the-general-population-adults-aged-15-64-in-bulgaria","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/last-12-months-prevalence-of-psychoactive-substance-use-among-the-general-population-adults-aged-15-64-in-bulgaria\/","title":{"rendered":"Last 12 months prevalence of psychoactive substance use among the general population (adults aged 15-64) in Bulgaria"},"content":{"rendered":"\n
\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n
Prevalence of psychoactive substance use<\/a>
Prevalence of medication use
Prevalence of drug use<\/a>
Drug prevention
Treatment supply<\/a>
Treatment demand
Health consequences<\/a>
Harm reduction<\/a>
Drug-related crimes<\/a>
Drug market<\/a>
Drug use and prison<\/a>
Monitoring of publications<\/a>
Attitudes to legal framework changes<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Source: National population adult survey on attitudes and use of psychoactive substances among the general population (aged 15-64). The survey was conducted in the period October-November 2024 on behalf of and with the methodological support of the National Focal Point on Drugs and Drug Addictions by Sova 5 Agency, covering 4002 individuals across the country, and using the “face-to-face” method with a tablet. <\/p>\n<\/div>\n\n\n\n

\n

Last 12 months prevalence of psychoactive substance use among the general population (adults aged 15-64) (by sex, 2024)<\/strong><\/p>\n\n\n\n

Type of psychoactive substances<\/strong><\/td>Males<\/strong><\/td>Females<\/strong><\/td>Total<\/strong><\/td>Lower (%)<\/strong><\/td>Upper (%)<\/strong><\/td>Lower (number)<\/strong><\/td>Upper (number)<\/strong><\/td><\/tr>
Tobacco products (total)<\/strong><\/td>61.7<\/strong><\/td>53.4%<\/strong><\/td>57.6%<\/strong><\/td>56.0%<\/strong><\/td>59.1%<\/strong><\/td>2 237 000<\/strong><\/td>2 359 000<\/strong><\/td><\/tr>
Cigarettes<\/td>57.0%<\/td>48.1%<\/td>52.6%<\/strong><\/td>51.1%<\/td>54.2%<\/td>2 039 000<\/td>2 162 000<\/td><\/tr>
Electronic cigarettes (vape)<\/td>27.7%<\/td>30.3%<\/td>29.4%<\/strong><\/td>28.0%<\/td>30.8%<\/td>1 118 000<\/td>1 231 000<\/td><\/tr>
Tobacco heating devices<\/td>10.0%<\/td>10.1%<\/td>10.0%<\/strong><\/td>9.1%<\/td>11.0%<\/td>364 000<\/td>438 000<\/td><\/tr>
Hookah<\/td>17.0%<\/td>10.3%<\/td>13.8%<\/strong><\/td>12.7%<\/td>14.8%<\/td>505 000<\/td>595 000<\/td><\/tr>
Alcohol<\/strong><\/td>91.5%<\/strong><\/td>81.7%<\/strong><\/td>86.7%<\/strong><\/td>85.6%<\/strong><\/td>87.7%<\/strong><\/td>3 417 000<\/strong><\/td>3 501 000<\/strong><\/td><\/tr><\/tbody><\/table>
Note: The confidence interval is calculated on a 95% confidence level.<\/sub><\/figcaption><\/figure>\n\n\n\n

Last 12 months prevalence of psychoactive substance use among the general population (adults aged 15-64) (by settlement, 2024)<\/strong><\/p>\n\n\n\n

Type of psychoactive substances<\/strong><\/td>Sofia (capital)<\/strong><\/td>District <\/strong>city<\/strong><\/td>Non-district city<\/strong><\/td>Village<\/strong><\/strong><\/td>Total<\/strong><\/td><\/tr>
Tobacco products (total)<\/strong><\/td>61.3%<\/strong><\/td>57.5%<\/strong><\/td>57.7%<\/strong><\/td>55.2%<\/strong><\/td>57.6%<\/strong><\/td><\/tr>
Cigarettes<\/td>56.6%<\/td>52.7%<\/td>53.9%<\/td>47.7%<\/td>52.6%<\/strong><\/td><\/tr>
Electronic cigarettes (vape)<\/td>30.5%<\/td>26.3%<\/td>31.6%<\/td>28.9%<\/td>29.4%<\/strong><\/td><\/tr>
Tobacco heating devices<\/td>11.8%<\/td>9.8%<\/td>9.5%<\/td>9.5%<\/td>10.0%<\/strong><\/td><\/tr>
Hookah<\/td>13.9%<\/td>14.4%<\/td>12.0%<\/td>14.5%<\/td>13.8%<\/strong><\/td><\/tr>
Alcohol<\/strong><\/td>85.9%<\/strong><\/td>86.8%<\/strong><\/td>87.7%<\/strong><\/td>86.1%<\/strong><\/td>86.7%<\/strong><\/td><\/tr>
Anabolic steroids<\/td>0.7%<\/td>0.5%<\/td>0.0%<\/td>0.2%<\/td>0.5%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n<\/div>\n\n\n\n

Lifetime prevalence of psychoactive substance use among the general population (adults aged 15-64) (by age groups, 2024)<\/strong><\/p>\n\n\n\n

Type of psychoactive substances<\/strong><\/td>15-24 (males)<\/strong><\/td>15-24 (females)<\/strong><\/td>15-24 (total)<\/strong><\/td>25-34 (males)<\/strong><\/td>25-34 (females)<\/strong><\/td>25-34 (total)<\/strong><\/td><\/tr>
Tobacco products (total)<\/strong><\/td>69.4%<\/strong><\/td>60.1%<\/strong><\/td>64.8%<\/strong><\/td>58.0%<\/strong><\/td>56.3%<\/strong><\/td>57.1%<\/strong><\/td><\/tr>
Cigarettes<\/td>61.5%<\/td>51.4%<\/td>56.5%<\/strong><\/td>53.2%<\/td>50.9%<\/td>52.0%<\/strong><\/td><\/tr>
Electronic cigarettes (vape)<\/td>54.5%<\/td>46.6%<\/td>50.6%<\/strong><\/td>30.8%<\/td>34.3%<\/td>32.6%<\/strong><\/td><\/tr>
Tobacco heating devices<\/td>17.2%<\/td>17.4%<\/td>17.3%<\/strong><\/td>15.1%<\/td>13.6%<\/td>14.3%<\/strong><\/td><\/tr>
Hookah<\/td>43.3%<\/td>26.4%<\/td>34.9%<\/strong><\/td>33.7%<\/td>21.1%<\/td>27.2%<\/strong><\/td><\/tr>
Alcohol<\/strong><\/td>89.5%<\/strong><\/td>77.5%<\/strong><\/td>83.5%<\/strong><\/td>91.3%<\/strong><\/td>75.0%<\/strong><\/td>82.9%<\/strong><\/td><\/tr>
Anabolic steroids<\/td><\/td><\/td>0.8%<\/strong><\/td><\/td><\/td>0.5%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
Type of psychoactive substances<\/strong><\/td>35-44 (males)<\/strong><\/td>35-44 (females)<\/strong><\/td>35-44 (total)<\/strong><\/td>45-54 (males)<\/strong><\/td>45-54 (females)<\/strong><\/td>45-54 (total)<\/strong><\/td>55-64 (males)<\/strong><\/td>55-64 (females)<\/strong><\/td>55-64 (total)<\/strong><\/td><\/tr>
Tobacco products (total)<\/strong><\/td>61.8%<\/strong><\/td>52.5%<\/strong><\/td>57.0%<\/strong><\/td>64.6%<\/strong><\/td>49.7%<\/strong><\/td>57.4%<\/strong><\/td>55.9%<\/strong><\/td>51.0%<\/strong><\/td>53.6%<\/strong><\/td><\/tr>
Cigarettes<\/td>57.0%<\/td>48.4%<\/td>52.5%<\/strong><\/td>59.8%<\/td>43.1%<\/td>52.2%<\/strong><\/td>53.8%<\/td>47.6%<\/td>50.9%<\/strong><\/td><\/tr>
Electronic cigarettes (vape)<\/td>25.5%<\/td>24.4%<\/td>24.9%<\/strong><\/td>26.5%<\/td>26.8%<\/td>26.6%<\/strong><\/td>15.3%<\/td>25.2%<\/td>19.9%<\/strong><\/td><\/tr>
Tobacco heating devices<\/td>10.3%<\/td>8.1%<\/td>9.2%<\/strong><\/td>8.9%<\/td>6.5%<\/td>7.8%<\/strong><\/td>3.1%<\/td>7.9%<\/td>5.3%<\/strong><\/td><\/tr>
Hookah<\/td>15.0%<\/td>7.7%<\/td>11.2%<\/strong><\/td>4.4%<\/td>2.8%<\/td>3.7%<\/strong><\/td>3.9%<\/td>1.0%<\/td>2.5%<\/strong><\/td><\/tr>
Alcohol<\/strong><\/td>92.8%<\/strong><\/td>81.1%<\/strong><\/td>86.7%<\/strong><\/td>93.1%<\/strong><\/td>87,1%<\/strong><\/td>90.3%<\/strong><\/td>89.9%<\/strong><\/td>85.0%<\/strong><\/td>87.6%<\/strong><\/td><\/tr>
Anabolic steroids<\/td><\/td><\/td>0.1%<\/strong><\/td><\/td><\/td>0.2%<\/strong><\/td><\/td><\/td>0.3%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"

Prevalence of psychoactive substance usePrevalence of medication usePrevalence of drug useDrug preventionTreatment supplyTreatment demandHealth consequencesHarm reductionDrug-related crimesDrug marketDrug use and prisonMonitoring of publicationsAttitudes to legal framework changes Source: National population adult survey on attitudes and use of psychoactive substances among the general population (aged 15-64). The survey was conducted in the period October-November 2024 on […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84,86],"tags":[],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/7995"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=7995"}],"version-history":[{"count":2,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/7995\/revisions"}],"predecessor-version":[{"id":7997,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/7995\/revisions\/7997"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=7995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=7995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=7995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}